Recombinant multi-species MYO15A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MYO15A protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes an unconventional myosin. This protein differs from other myosins in that it has a long N-terminal extension preceding the conserved motor domain. Studies in mice suggest that this protein is necessary for actin organization in the hair cells of the cochlea. Mutations in this gene have been associated with profound, congenital, neurosensory, nonsyndromal deafness. This gene is located within the Smith-Magenis syndrome region on chromosome 17. Read-through transcripts containing an upstream gene and this gene have been identified, but they are not thought to encode a fusion protein. Several alternatively spliced transcript variants have been described, but their full length sequences have not been determined. [provided by RefSeq, Jul 2008]
The Alternative Names of target: DFNB3,MYO15,MYO15A,Myo15,Myo15a,RGD1561873,Unconventional myosin-15,Unconventional myosin-XV,sh-2,sh2

Target products collectionGo to MYO15A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP9319-Ag-1/ GM-Tg-hg-IP9319-Ag-2 Human MYO15A protein Human
GM-Tg-rg-IP9319-Ag-1/ GM-Tg-rg-IP9319-Ag-2 Rat MYO15A protein Rat
GM-Tg-mg-IP9319-Ag-1/ GM-Tg-mg-IP9319-Ag-2 Mouse MYO15A protein Mouse
GM-Tg-cynog-IP9319-Ag-1/ GM-Tg-cynog-IP9319-Ag-2 Cynomolgus/Rhesus macaque MYO15A protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP9319-Ag-1/ GM-Tg-felg-IP9319-Ag-2 Feline MYO15A protein Feline
GM-Tg-cang-IP9319-Ag-1/ GM-Tg-cang-IP9319-Ag-2 Canine MYO15A protein Canine
GM-Tg-bovg-IP9319-Ag-1/ GM-Tg-bovg-IP9319-Ag-2 Bovine MYO15A protein Bovine
GM-Tg-equg-IP9319-Ag-1/ GM-Tg-equg-IP9319-Ag-2 Equine MYO15A protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP9319-Ag-1/ GM-Tg-hg-IP9319-Ag-2; GM-Tg-rg-IP9319-Ag-1/ GM-Tg-rg-IP9319-Ag-2;
GM-Tg-mg-IP9319-Ag-1/ GM-Tg-mg-IP9319-Ag-2; GM-Tg-cynog-IP9319-Ag-1/ GM-Tg-cynog-IP9319-Ag-2;
GM-Tg-felg-IP9319-Ag-1/ GM-Tg-felg-IP9319-Ag-2; GM-Tg-cang-IP9319-Ag-1/ GM-Tg-cang-IP9319-Ag-2;
GM-Tg-bovg-IP9319-Ag-1/ GM-Tg-bovg-IP9319-Ag-2; GM-Tg-equg-IP9319-Ag-1/ GM-Tg-equg-IP9319-Ag-2
Products Name MYO15A protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name MYO15A
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MYO15A protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.